title: NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer.
authors.affiliation: National Institute for Health and Care Excellence, Manchester M1 4BT, UK. Electronic address: ahmed.elsada@nice.org.uk.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Elsada
authors.affiliation: National Institute for Health and Care Excellence, Manchester M1 4BT, UK.
authors.forename: Sally
authors.initials: S
authors.lastname: Doss
authors.affiliation: National Institute for Health and Care Excellence, Manchester M1 4BT, UK.
authors.forename: Janet
authors.initials: J
authors.lastname: Robertson
authors.affiliation: National Institute for Health and Care Excellence, Manchester M1 4BT, UK.
authors.forename: E Jane
authors.initials: EJ
authors.lastname: Adam
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D000069287:Capecitabine / Q000008:administration & dosage; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008453:Maytansine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D017410:Practice Guidelines as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D000068878:Trastuzumab; D006113:United Kingdom
chemical_list: D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized; D000069287:Capecitabine; D008453:Maytansine; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human